Clinical trial NCT02350023: Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata
Official title: A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Alopecia Areata
Keywords: alopecia areata
betamethasone
latanoprost
topical steroid
prostaglandin
Lead sponsor: PIMERIndia
Sponsor class: UNKNOWN
First posted: 2015-01-29
Enrollment: 50
Sex: ALL
Maximum age (years): 99
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. The two agents have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.

Detailed description: Alopecia areata (AA) is an autoimmune disease that involves the hair follicles. Topical corticosteroids are the established agents for treating this disorder. Topical prostaglandins like latanoprost have also been used for this disorder. There are several case reports and case series which have demonstrated the efficacy of topical prostaglandins. However, the two agents i.e. topical corticosteroids and topical latanoprost have not been compared head-to-head in the published literature. The investigators attempt to compare the efficacy and safety of topical betamethasone and topical latanoprost in the treatment of localised alopecia areata.

Eligibility criteria: Inclusion Criteria:

* • Cases of AA involving scalp and beard area, having 5 or less patches in all, involving less than 40% area

  * Stable disease without appearance of new patch or increase in size of existing patch for at least 15 days

Exclusion Criteria:

* • Pregnant and lactating women

  * Patients on topical treatment for alopecia in the past fifteen days or on systemic treatment for alopecia in the past one month
  * Presence of any contraindication for topical corticosteroids (local skin infections, skin atrophy) or latanoprost (pregnancy, lactation and dermatitis)
  * Any other coexisting hair disorder (viz., trichotillomania, androgenetic alopecia, telogen effluvium)
  * Extensive disease i.e. \>5 patches of AA or area involving \>40% area / alopecia totalis/ alopecia universalis/ ophiasis

Primary outcomes:
measure: Number of patients with hair regrowth (complete, partial, or no regrowth)
timeFrame: 4 months
Secondary outcomes:
measure: Number of patients suffering from adverse effects
timeFrame: 4 months
Other outcomes:
Locations:
city: Chandigarh
country: India
facility: Dept of Dermatology, PGIMER
Study officials:
References:
citation: Bhat S, Handa S, De D. A randomized comparative study of the efficacy of topical latanoprost versus topical betamethasone diproprionate lotion in the treatment of localized alopecia areata. Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):42-48. doi: 10.25259/IJDVL_787_19.